Effects of Smoking on the Pharmacokinetics of Erlotinib
Open Access
- 1 April 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (7), 2166-2171
- https://doi.org/10.1158/1078-0432.ccr-05-2235
Abstract
Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental Design: This was a single-center, open-label pharmacokinetic study in healthy male subjects. Subjects were enrolled into two treatment cohorts based on smoking status (current smokers and nonsmokers). The pharmacokinetic profile for erlotinib and its metabolite, OSI-420, was determined for each subject following each treatment. Results: Current smokers achieved significantly less erlotinib exposure following a single 150 or 300 mg dose than nonsmokers. Following the 150 mg dose, the geometric mean erlotinib AUC0-∞ in smokers was 2.8-fold lower than in nonsmokers and similar to that of nonsmokers at the 300 mg dose. Cmax in smokers was two-thirds of that in nonsmokers, and C24h in smokers was 8.3-fold lower than in nonsmokers. The median C24h of smokers at the 300 mg dose was slightly less than the C24h of smokers at the 150 mg dose. The median Cmax was greater in smokers at the 300 mg dose than in nonsmokers at the 150 mg dose. Conclusion: This study confirms that the pharmacokinetics of erlotinib is different in current smokers and nonsmokers. The observation that AUC0-∞ and C24h were significantly decreased in smokers compared with nonsmokers, and a smaller decrease in Cmax was observed, is consistent with increased metabolic clearance of erlotinib in current smokers.Keywords
This publication has 23 references indexed in Scilit:
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2005
- P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?Lung Cancer, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Smoking in Patients Receiving Psychotropic MedicationsCNS Drugs, 2001
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- Recent Developments in the Study of the Effects of Cigarette Smoking on Clinical Pharmacokinetics and Clinical PharmacodynamicsClinical Pharmacokinetics, 1989
- Metabolism of flecainideThe American Journal of Cardiology, 1984
- Influence of Cigarette Smoking on Drug Metabolism in ManDrug Metabolism Reviews, 1979
- The influence of smoking on the intersubject variation in pentazocine elimination.British Journal of Clinical Pharmacology, 1976
- THE HEMODYNAMIC EFFECTS OF PROPRANOLOL HYDROCHLORIDE AFTER SMOKINGThe American Journal of the Medical Sciences, 1967